more

Mirati Therapeutics, Inc. (MRTX)

(Delayed Data from NSDQ)

$63.93 USD

+2.52 (4.10%)

Updated May 3, 2019 04:00 PM ET

After-Market: $64.05 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Zacks News

4 Drug/Biotech Outperformers That May Lose Steam in 2020

by Kinjel Shah Published on December 19,2019

Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.

pharmaceuticals

Options Traders Expect Huge Moves in Mirati (MRTX) Stock

by Zacks Equity Research Published on December 18,2019

Investors need to pay close attention to Mirati (MRTX) stock based on the movements in the options market lately.

MRTXPositive Net Change

medical

Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on November 04,2019

Mirati (MRTX) delivered earnings and revenue surprises of -8.66% and 97.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

MRTXPositive Net Change

Are Options Traders Betting on a Big Move in Mirati Therapeutics (MRTX) Stock?

by Zacks Equity Research Published on October 01,2019

Investors need to pay close attention to Mirati Therapeutics (MRTX) stock based on the movements in the options market lately.

MRTXPositive Net Change

medical

Amgen's KRAS Inhibitor Shows Response in Larger NSCLC Group

by Zacks Equity Research Published on September 09,2019

Amgen's (AMGN) novel investigational KRAS inhibitor, AMG 510, for solid tumor shows anti-tumor activity in a larger group of NSCLC patients.

biotechs

Mirati Inks Deal with Novartis to Evaluate Tumor Candidate

by Zacks Equity Research Published on July 10,2019

Mirati (MRTX) inks a clinical collaboration with Novartis to evaluate the combination of the former's MRTX849 and the latter's SHP2 inhibitor, TNO155, in patients with advanced solid tumors.

biotechs

Implied Volatility Surging for Mirati Therapeutics (MRTX) Stock Options

by Zacks Equity Research Published on June 14,2019

Investors need to pay close attention to Mirati Therapeutics (MRTX) stock based on the movements in the options market lately.

MRTXPositive Net Change

biotechs

Amgen's KRAS Inhibitor Shows Impressive Anti-Tumor Activity

by Zacks Equity Research Published on June 04,2019

At ASCO, Amgen (AMGN) presented encouraging initial data set for AMG 510, its novel investigational KRAS inhibitor for solid tumor.

biotechs

Why Cancer-Fighting Stocks & ETFs Are Soaring

by Neena Mishra Published on June 03,2019

The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.